Business in the Burbs

Regeneron reaches royalty agreements for two medications

June

Regeneron Pharmaceuticals Inc., a biotech company based in Tarrytown, said it has entered into two royalty agreements with Novartis Pharma AG covering two medications that the companies have been developing.

Under the first royalty agreement, Regeneron said it is entitled to receive royalties on worldwide sales of Novartis’ canakinumab, a medication currently under regulatory review to treat inflammatory diseases. Under the second royalty agreement, Novartis is entitled to receive royalties on worldwide sales of a second-generation interleukin-1 Trap, another treatment for inflammatpry diseases, if development proceeds.

This entry was posted on Thursday, June 11th, 2009 at 1:04 pm by Jay Loomis.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.